相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
James Larkin et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Reinhard Dummer et al.
LANCET ONCOLOGY (2018)
Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials
Alberto Carretero-González et al.
Oncotarget (2018)
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0
Ryan J. Sullivan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis
Ahmad Tarhini et al.
IMMUNOTHERAPY (2018)
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Frank Stephen Hodi et al.
LANCET ONCOLOGY (2018)
Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma
Christine G. Kohn et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition
Douglas B. Johnson et al.
JOURNAL OF IMMUNOTHERAPY (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G. V. Long et al.
ANNALS OF ONCOLOGY (2017)
Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?
Matteo S. Carlino et al.
CLINICAL CANCER RESEARCH (2016)
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
F. Stephen Hodi et al.
LANCET ONCOLOGY (2016)
PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses
Patrick J. Medina et al.
PHARMACOTHERAPY (2016)
PREDICTORS OF UTILITY OVER TIME AMONG PATIENTS WITH TREATMENT-NAIVE ADVANCED MELANOMA FROM THE PHASE 3 CHECKMATE 067 TRIAL
V Paly et al.
VALUE IN HEALTH (2016)
Efficacy of immunotherapy in advanced melanoma: A network meta-analysis.
Belal Firwana et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V. Long et al.
LANCET (2015)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al.
LANCET ONCOLOGY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective
Nigel Fleeman et al.
PHARMACOECONOMICS (2015)
COST-EFFECTIVENESS OF PEMBROLIZUMAB FOR UNRESECTABLE METASTATIC MELANOMA AFTER PROGRESSION WITH IPILIMUMAB IN ENGLAND
E. Marriott et al.
VALUE IN HEALTH (2015)
Dabrafenib in combination with trametinib for the treatment of metastatic melanoma
Mark M. Awad et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2015)
Systemic treatment for BRAF-mutant melanoma: where do we go next?
Alexander M. Menzies et al.
LANCET ONCOLOGY (2014)
Updating Cost-Effectiveness - The Curious Resilience of the $50,000-per-QALY Threshold
Peter J. Neumann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
James Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Which drug, and when, for patients with BRAF-mutant melanoma?
Sekwon Jang et al.
LANCET ONCOLOGY (2013)
Vemurafenib for the Treatment of Locally Advanced or Metastatic BRAF V600 Mutation-Positive Malignant Melanoma: A NICE Single Technology Appraisal
Sophie Beale et al.
PHARMACOECONOMICS (2013)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Modeling using Discrete Event Simulation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4
Jonathan Karnon et al.
VALUE IN HEALTH (2012)
Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis
Victor Barzey et al.
JOURNAL OF MEDICAL ECONOMICS (2012)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Societal preference values for advanced melanoma health states in the United Kingdom and Australia
K. M. Beusterien et al.
BRITISH JOURNAL OF CANCER (2009)
Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
Axel Hauschild et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
MR Middleton et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
